Kornimate/medical-research-clean huggingface dataset:
effects of enteral nutrition and corticosteroid on intestinal flora in induction remission of crohn disease in adult

Conditions: Crohn Disease

Summary: the pathogenesis of crohn disease (cd) is unknown, but there is evidence show that the inadequate immune response or overreaction of the immune system against food antigens or components of the commensal flora involve it. corticosteroid therapy is effective for adult patients with cd, but it has side effects and can't promote mucosal healing. in recent years, enteral nutrition (en) is becoming primary therapy in induction and maintenance remission of cd, especially in children. but the mechanism of en in induction and maintenance remission of cd is still unclear, and parts of patient have good clinical response to en therapy while other don't. so we design the study to explore whether en treats cd by effecting intestinal flora and whether the intestinal flora of patient with cd relates with clinical response.

the pathogenesis of cd is unknown, but there is evidence show that the inadequate immune response or overreaction of the immune system against food antigens or components of the commensal flora involve it. corticosteroid therapy is effective for adult patients with cd, but it has side effects and can't promote mucosal healing. in recent years, en is becoming primary therapy in induction and maintenance remission of cd, especially in children. but the mechanism of en in induction and maintenance remission of cd is still unclear, and parts of patient have good clinical response to en therapy while other don't. so we design the study to explore whether en treats cd by effecting intestinal flora and whether the intestinal flora of patient with cd relates with clinical response.

Eligibility criteria:
inclusion criteria: 1. patients should be in the age range of 18 - 75 years; 2. patients should have clinical, imaging, endoscopic and histological diagnosis of cd based on who criteria 3. patients should have a cdai score of more than 150 and have a crp level of more than 10mg/l at enrollment; 4. patients will not be excluded if they have received 5-asa(aminosalicylic acid) or immunomodulator for \>8 weeks and the dose is stable 5. informed consent exclusion criteria: 1. patients who can't tolerate enteral nutrition because of complications, such as complete intestinal obstruction, gastrointestinal perforation or bleeding etc. 2. patients who receive corticosteroids or enteral nutrition or prebiotics /probiotics/synbiotics/antibiotic treatment in the previous 4 weeks. 3. patients who accompanied extra-intestinal manifestations, serve complications, and active perianal disease and need other drug therapies. 4. patients who had ostomy or colectomy or subtotal colectomy 5. patients with end-stage disease or is expected likely to die during the study 6. patients are participating in other clinical trials or participated within 6 months prior to this study
gls-010 monotherapy versus chemotherapy in patients with relapsed or refractory classical hodgkin's lymphoma (r/r chl)

Conditions: Classic Hodgkin's Lymphoma; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma

Summary: the primary objective of this study is to evaluate the efficacy of gls-010 in participants with relapsed or refractory classical hodgkin lymphoma (r/r chl), as measured by progression-free survival (pfs) as assessed by irrc


Eligibility criteria:
key inclusion criteria: 1. signed written informed consent form (icf). 2. age of ≥ 18 years at the time of enrollment. 3. histologically confirmed classic hodgkin's lymphoma (chl). 4. subjects required relapsed or refractory ,failure to at least 2 lines of prior systemic chemotherapy. 5. patients who have failed prior vibutuximab treatment or are unwilling or not eligible for vibutuximab treatment 6. have at least one measurable lesion according to lugano classification 2014 and fdg-pet was positive. 7. eastern cooperative oncology group (ecog) performance status of 0 or 1. 8. life expectancy of ≥ 12 weeks. 9. have adequate hematologic and organ function . key exclusion criteria: 1. nodular lymphocytes are non-hodgkin's lymphoma or gray area lymphoma. 2. central nervous system lymphoma invasion. 3. subjects requiring systemic corticosteroids or other immunosuppressive agents within 14 days prior to screening or during the study period. 4. prior exposure to any anti-pd-1, anti-pd-l1,anti-pd-l2, anti-cd137,anti-ctla-4 antibody, or any other antibody or drug target for t cell co-stimulatory or checkpoint pathways. 5. known human immunodeficiency virus (hiv), or serologic status reflecting active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. 6. subjects with other malignancy within 5 years prior to the first dose of study treatment, except for cervical carcinoma in situ and cured basal cell carcinoma of the skin. 7. have received chemotherapy, radiotherapy, molecular-targeted therapy or major surgery within 4 weeks prior to the first dose of study treatmen; clinically significant ae associated with previous treatment has not returned to baseline or ≤1 (except hair loss). 8. pregnant or breast-feeding women. 9. patients are unsuitable for the study evaluated by investigator.

Keywords: gls-010 relapsed or refractory classic hodgkin's lymphoma
effect of tadalafil administration on vasodilatation mediated by flow in patients with obesity grade i-ii

Conditions: Obesity and Erectile Dysfuntion

Summary: obesity is a public health problem, not only for its high prevalence, but also because of the comorbidities found in it. within the physiopathological mechanisms associated with obesity is a low-grade inflammatory state that is associated with endothelial dysfunction endothelial dysfunction is known to be the beginning of the atherosclerotic process that eventually leads to the development of cardiovascular disease. erectile dysfunction is an example of endothelial dysfunction, where blood flow is compromised as a consequence of a reduction in the production of nitric oxide among others. tadalafil, which is an inhibitor of pde-5, is currently used as a treatment for erectile dysfunction. however, it has been observed that the administration of tadalafil in patients with éndothelial dysfunction decreases arterial stiffness, having a positive effect on it, in addition it reduces the pulse pressure, systolic and diastolic pressure.

: the objective is to evaluate the effect of administration of tadalafil on vasodilatation mediated by flow in patients with obesity grade i-ii and erectil dysfunction. a double-blind clinical trial with randomization and control group will be carried out. male patients aged 25-60 years, bmi ≥30, without comorbidities will be included. they should not be under treatment with ipde5 or statins, nor should they have uncontrolled ischemic heart disease. to carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally and the second will receive 20 mg of calcined magnesia (placebo),after a single administration, 24 hours later the investigators are going to evaluate vasodilatation mediated by. in addition, they will have a metabolic profile at the beginning. for the analysis of results the statistical program spss version 21 for windows will be used. the results will be expressed in averages and standard deviation and normality tests will be applied such as kolmogorov smirnof, shapiro wilk, as well as the willcoxon and u mann whitney test.

Eligibility criteria:
inclusion criteria: * male patients * age 25 to 60 years * obesity grade i-ii * .sign the inform consent form. * answer the questionary iife exclusion criteria: . dm 1-2 * systemic arterial hypertension * uncontrolled mixed dyslipidemia or under hypolipemiant treatment with statins. * active smoking * precedent of uncontrolled ischemic cardiopathy. * use of anti-inflammatory drugs, including acetylsalicylic acid, antihypertensive, antihyperglucemic, anti-anginal drugs, recent use of antiviral drugs that contains vasoconstrictors. * hepatic, renal, thyroid, and/or pulmonary decompensated disease. * the precedent of hypersensibility to the phosphodiesterase-5 inhibitors. * patients that are under treatmen with ipde
flexiquit+: web program to promote smoking cessation in sexual and gender minority young adult smokers

Conditions: Tobacco Use Disorder

Summary: this phase i trial studies how well flexiquit+ helps young adult smokers who identify as a sexual and/or gender minority to quit or cut down on smoking. flexiquit+ is an avatar-led, web-based intervention that can help smokers quit or cut back on how much they smoke cigarettes and/or vape, reducing their chances of developing tobacco-related health conditions.

outline: individuals will be recruited to use the flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. participants will also receive text messages providing motivational messages and review information discussed in the program. at the end of the intervention, participants will receive an email with all of the session handouts. participants are followed up with at 2 months.

Eligibility criteria:
inclusion criteria: * participants must self-identify as a sexual and/or gender minority (i.e., a sexual orientation other than straight and/or gender that doesn't match sex assigned at birth) * participants must currently reside in the united states and anticipate remaining in the united states for the duration of the study (2 months) * participants must self-report smoking at least 1 cigarette per day in the 30 days prior to screening * participants must self-report having at least weekly internet access for the next two months * participants must self-report being willing and able to stream video online for this study * participants must self-report current use of a personal email account * participants must self-report current use of text messaging * participants must self-report that they are interested in participating in the study for themselves (versus \[vs\] someone else) * participants must self-report that they are not currently taking part in any other smoking cessation treatment such as the nicotine patch, nicotine gum, zyban, in-person counseling, telephone counseling, using a web-based or app-based cessation program * participants must self-report that they have not participated in one of our prior smoking cessation studies, including the user-centered research conducted in the development of flexiquit+ * participants must self-report that they are comfortable reading, writing, and speaking english * participants must self-report that they understand and agree to the conditions of compensation * participants must self-report that they are not currently incarcerated in a prison * participants must be willing to use the flexiquit+ program, complete the study assessments, and sign an online consent form
efficacy and safety of the pain relieving effect of dronabinol in central neuropathic pain related to multiple sclerosis

Conditions: Central Neuropathic Pain in Multiple Sclerosis

Summary: the purpose of this study is to determine whether dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

multiple sclerosis (ms) is in all probability an autoimmune disease causing severe neurological disability due to inflammation and degeneration in the central nervous system (cns). ms affects over 1 million people worldwide. central neuropathic pain is associated with approximately 30% of all patients with ms. ms-accompanying pain has a major impact on the patients' quality of life as usual conventional analgesics are little effective. the aim of this clinical study is to determine whether dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis acc. to mcdonald diagnostic criteria * edss score between 3 and 8 (incl.) * patients who are in a stable phase of multiple sclerosis * patients with ms-related central neuropathic pain for at least 3 months exclusion criteria: * severe concomitant diseases * certain concomitant therapies (in particular: pain influencing concomitant therapies) * dronabinol intake within the last 12 months prior to study entry or marihuana use within one month prior to study entry

Keywords: dronabinol (-)trans-delta9-tetrahydrocannabinol central neuropathic pain multiple sclerosis analgesic central neuropathic pain related to multiple sclerosis
optimizing fitness: post bariatric surgery with modified qigong breathing exercise

Conditions: Bariatric Surgery

Summary: bariatric surgery has been reported to be the most effective treatment option for losing and maintaining body weight and improving comorbidities and mortality associated with morbid obesity. nevertheless, even though physical activity is recommended to optimize bariatric surgery results. very little is known, about whether engaging in an exercise program after surgery can provide additional improvement in health outcomes. while to date there are relatively few researches studied the effect of exercise in patients who have undergone bariatric surgery. this study was conducted to explore the influence of modified qigong breathing exercise on pulmonary function, endurance and fitness on post bariatric surgery patients. qigong as ancient chinese traditional medicine have been documented to be effective in treating obesity. literature showing that the desire to eat and the feeling of hunger, along with prospective food consumption in patients with obesity.

bariatric surgery has been reported to be the most effective treatment option for losing and maintaining body weight and improving comorbidities and mortality associated with morbid obesity. nevertheless, even though physical activity is recommended to optimize bariatric surgery results. very little is known, about whether engaging in an exercise program after surgery can provide additional improvement in health outcomes. while to date there are relatively few researches studied the effect of exercise in patients who have undergone bariatric surgery. this study was conducted to explore the influence of modified qigong breathing exercise on pulmonary function,endurance and fitness on post bariatric surgery patients. bariatric surgery has been reported to be the most effective treatment option for losing and maintaining body weight and improving comorbidities and mortality associated with morbid obesity. nevertheless, even though physical activity is recommended to optimize bariatric surgery results. very little is known, about whether engaging in an exercise program after surgery can provide additional improvement in health outcomes. while to date there are relatively few researches studied the effect of exercise in patients who have undergone bariatric surgery. qigong as ancient chinese traditional medicine have been documented to be effective in treating obesity. literature showing that the desire to eat and the feeling of hunger, along with prospective food consumption in patients with obesity .

Eligibility criteria:
inclusion criteria: * both male and fem * age ranged from 18-25 years old * at least 6 months after bs exclusion criteria: * patients with nerve root compression * spine disorders * spinal fracture * previous spinal surgery * pregnancy * lower limb injury * any contraindication to the exercise therapy

Keywords: fitness bariatric surgery qigong breathing exercise
a patient-centered asthma management communication intervention for rural latino children

Conditions: Asthma

Summary: the purpose of this research is to develop and evaluate an mhealth communication intervention designed to improve asthma medication adherence amongst rural latino children in south carolina.

the overall prevalence of asthma is highest in the us south, which has one of the fastest growing latino populations in the country. in south carolina, asthma is the leading cause of children's hospitalization and emergency department (ed) visits, with significant direct and indirect costs. although rates of childhood asthma are lower in latinos (with the exception of children of puerto rican origin) than in whites, latinos are more likely to have a higher incidence of uncontrolled asthma symptoms, ed visits, repeat hospitalizations, and poorer health in general. current interventions addressing asthma control include outpatient clinic based and home visitation programs. rural latino families have difficulty participating with these types of programs due to work, family, and transportation constraints. the adaptability of mobile apps holds the potential to target the unique challenges to management experienced by rural latino children with asthma experience. the goal of this study is to develop and evaluate a patient-centered collaborative intervention between rural latino children with asthma and their families, school-based nursing, and primary care providers, facilitated by the use of a smart phone based bilingual mobile app. the specific aims are to: 1. produce and validate a spanish translation of an existing asthma management app and evaluate its usability with latino parents of children with asthma; and 2. develop and evaluate a triadic, patient-centered asthma intervention preliminary protocol, facilitated by the bilingual mobile app validated in aim 1.

Eligibility criteria:
inclusion criteria: 1) children self/family-identified as hispanic/latino or african american, 2) school-aged (5-18 years) and attends school within the lancaster county school district, 3) has received a diagnosis of asthma from a health care provider and is taking a controller medication, and 4) parents/primary caregiver (e.g., grandparents, extended family) language of preference is spanish or english.

Keywords: mhealth latino asthma limited english proficiency pediatrics school nursing
effect of cardiac rehabilitation on health status, emotional outcomes, and 90-day readmission rate among cardiac surgery patients

Conditions: Health Status; Anxiety; Depression; 90-day Readmission

Summary: this study aims to investigate the effect of the cardiac rehabilitation program on perceived health, status, anxiety, depression, and 90-day readmission rates for post-cardiac surgery patients. the participants in this study will be randomly allocated to either an experimental or control group, the experimental group will receive the cardiac rehabilitation programthe cardiac rehabilitation program extends over 3 months after cardiac surgery. the program includes exercise, health education, and stress management. all content will delivered to the participants through the whatsapp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation..etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. all interventions are guided by universal guidelines like the australian cardiovascular health and rehabilitation association (acra) and american heart association (aha)..all potential participants will be assessed before being involved in the study. assessment including a general physical examination, inspection of the surgical site, and recent history for potential patient symptoms after discharge, such as chest pain, palpitation, fatigue, or dyspnea. the assessment includes electrocardiograph (ecg), blood samples, and echocardiography analyses. based on the findings of this assessment, patients will be classified by the cardiologist as either grade i, ii, iii, or iv, according to the new york heart association (nyha) classification. patients who will be eligible to participate in the present study should be grade i or ii in the nyha classification for dyspnea. participants in the control group will receive the usual care (general instructions and advice from physicians and nurses). all materials will be delivered to all participants after completing the study.


Eligibility criteria:
inclusion criteria: 1. . aged over 18 years. 2. underwent cardiac surgery. 3. classified as grade i or ii according to nyha classification of dyspnea by the physician. 4. does not complain of any physical or mental condition preventing him or her from participating. 5. agree to participate in the study. exclusion criteria: 1. aged under 18 years. 2. classified as grade iii or iv according to nyha classification of dyspnea by the physician. 3. complain of any physical or mental condition preventing him or her from participating.
dietary optimization of microbiome recovery following fecal microbiota transplantation

Conditions: Recurrent Clostridium Difficile Infection; Fecal Microbiota Transplant

Summary: recurrent clostridioides difficle infection (rcdi) is a very significant problem in its own right and current fecal microbiota transplant (fmt) -based therapeutics will benefit from their optimization for this indication. it is likely that appropriate nutritional support coupled with microbiota-based drugs will yield superior clinical outcomes. however, both diet and gut microbiome are very complex. this project, which is based on a wealth of fmt experience, both clinical and investigational, over the past decade along with the novel techniques developed to identify dietary patterns and food groups that explain the most variation in gut microbiome, offers an ideal platform for performing systematic research in nutritional support that promotes gut microbiota health. the purpose is to generate preliminary data with regards to tolerability of the microbiota enhancing and nourishing diet (mend) and its effects on the fecal microbiota in rcdi patients following fmt with the goal of developing larger clinical trials aimed to optimize post-fmt dietary management.


Eligibility criteria:
inclusion criteria: * informed consent * clinical plans to undergo fmt therapy for treatment of rcdi (≥ 2 cdi recurrences following the initial episode within 1 year without contraindications to the treatment) * ability to comply with study requirements * age at least 18 years old exclusion criteria: * underlying ibd * history of stomach surgery or bowel resection * anticipated antibiotic exposure during the study period * advanced liver disease * ongoing alcohol or drug abuse * pregnancy * any reason felt by the investigator to complicate the feasibility of participation
does low dose of dexamethasone enhance analgesic quality of caudal analgesia in children undergoing orchiopexy?

Conditions: Patients With Cryptorchism Who Are Planning to Undergo Orchiopexy

Summary: caudal block is one of the most effective modalities to reduce pain both during and after the surgery involving areas under the umbilicus. according to previous research, 0.5mg/kg-1.5mg/kg dexamethasone is known to enhance the analgesic quality of caudal block in children. despite the fact that this high dose of dexamethasone is used to treat airway edema in actual practice and no adverse side effect related to dosage has been reported, it is 3 to 15 times higher than the daily antiemetic dose of dexamethasone that is used in standard care of anesthesia. therefore, our study aims to assess the effect of the more practical, antiemetic dose of dexamethasone (0.15mg/kg) as an adjuvant to enhance the quality of caudal block through a non-inferiority trial.


Eligibility criteria:
inclusion criteria: 1. ages from 6 months old to 6 years old 2. body weight less than or equal to 16.7kg 3. american society of anesthesiologists (asa) classification i or ii 4. patients receiving orchiopexy under general anesthesia exclusion criteria: 1. patients with uncorrected cardiac anomalies 2. patients with vertebral anomalies 3. diagnosis of diabetes mellitus 4. diagnosis of adrenal disease 5. currently on steroid 6. body temperature above 37.5'c preoperatively 7. allergy to dexamethasone 8. laparoscopic surgery

Keywords: caudal block low dose dexamethasone postoperative pain